Less than 3% of all people in the U.S. who are eligible for injectable weight loss drugs get a prescription for it, a new ...

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...

Weight loss drugs Ozempic and Wegovy would no longer be covered by California's health insurance for low-income people under ...

A recent study presented at the European Congress on Obesity reveals that individuals using weight loss drugs, including ...

California is not required by federal law to cover the cost of the weight loss drugs in its Medi-Cal program. Instead, the state opted to include them. Under Newsom’s proposed cuts, when Ozempic is ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

The analysis of 11 weight-loss drug studies by the University of Oxford found that patients typically lost 8kg (18lb) after ...

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Weight loss drugs have been pitted against each other in a first of its kind head-to-head trial. Mounjaro and Wegovy were put ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...